- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mo | Silexion Therapeutics Corp: Silexion Therapeutics Announces 1-for-24 Reverse Share Split | 3 | GlobeNewswire (USA) | ||
| Mo | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 26.10. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 30.09. | Silexion Therapeutics Corp: Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer | 242 | GlobeNewswire (Europe) | Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancer Integrated regimen combines direct EUS-guided intratumoral delivery... ► Artikel lesen | |
| 29.09. | Silexion raises $837,000 through warrant exercise at reduced price | 3 | Investing.com | ||
| 29.09. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Exercise of Warrants | 1 | GlobeNewswire (USA) | ||
| 29.09. | Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On | 5 | Benzinga.com | ||
| 28.09. | Silexion reports preclinical data on SIL204 delivery mechanism | 1 | Investing.com | ||
| 28.09. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers | 299 | GlobeNewswire (Europe) | Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdown Findings validate that physiological lipoprotein... ► Artikel lesen | |
| 25.09. | Silexion Therapeutics Corp - 8-K, Current Report | 3 | SEC Filings | ||
| 21.08. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 14.08. | Silexion Therapeutics GAAP EPS of -$5.17 | 1 | Seeking Alpha | ||
| 14.08. | Silexion Therapeutics Corp - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 14.08. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | 917 | GlobeNewswire (Europe) | Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center... ► Artikel lesen | |
| 12.08. | Silexion Therapeutics prices $2.5M public offering | 2 | Seeking Alpha | ||
| 12.08. | Silexion Therapeutics prices $2.5M public offering at $0.65 | 4 | Investing.com | ||
| 12.08. | Silexion Therapeutics, Inc.: Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering | 4 | GlobeNewswire (USA) | ||
| 10.08. | Silexion Therapeutics Corp - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 10.08. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 07.08. | Silexion Therapeutics Corp - S-1, General form for registration of securities | 1 | SEC Filings |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,70 | +0,77 % | 16,6 Milliarden Euro bei BioNTech, 15 neue Therapeuten bei Emyria - woran die Psychedelika-Medizin wirklich hängt | ||
| VALNEVA | 2,655 | +2,04 % | Valneva meldet positive Phase-2-Daten für Shigellen-Impfstoff | Valneva hat mit seinem Impfstoffkandidaten S4V2 gegen Shigellose positive Ergebnisse aus zwei klinischen Phase-2-Studien erzielt. In einer US-amerikanischen Studie mit kontrollierter Infektion gesunder... ► Artikel lesen | |
| AMGEN | 416,60 | -0,01 % | Biotech-Boom: Eli Lilly wächst rasant, Amgen legt nach - und Mesoblast liefert Zelltherapie-Umsätze | ||
| NOVAVAX | 9,150 | +0,22 % | Novavax, Inc.: Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights | Reports total revenue of $68 million for the third quarter of 2026Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and... ► Artikel lesen | |
| BIOGEN | 225,45 | -0,60 % | Biogen Inc.: ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure | Dapirolizumab pegol (DZP) associated with higher response rates using the novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): A post-hoc analysis applying TRM-SLE to the DZP... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 7,170 | +2,72 % | This Palatin Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday | ||
| OCUGEN | 0,822 | -3,07 % | Ocugen meldet Quartalszahlen: Warum der Rebound noch nicht trägt | ||
| VIKING THERAPEUTICS | 25,800 | +0,39 % | Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner? | ||
| INTELLIA THERAPEUTICS | 10,160 | +1,40 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TEMPUS AI | 73,02 | +1,23 % | Ihre wichtigsten Termine: Frische Q-Zahlen von Apple, Palantir, BioMarin, Marriott International, Fox Corp | © Foto: Andrej Sokolow - dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: US0378331005... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 0,744 | +5,08 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,694 | -0,71 % | BioCryst Pharmaceuticals (NDQ:BCRX): The Market Is Valuing ORLADEYO, But Is Navenibart The Real Prize? | ||
| NUREXONE BIOLOGIC | 0,317 | +3,93 % | 200 Prozent Ausbeute, 1 geplanter GMP-Partner: Warum NurExone und Made Scientific die Exosomenproduktion skalieren wollen | ||
| BIOMARIN PHARMACEUTICAL | 51,10 | -0,20 % | BioMarin Pharmaceutical (NDQ:BMRN): The Market Sees A Mature Slow-Growth Biotech, But Is It Missing The Next Growth Leg? | ||
| EXELIXIS | 64,20 | +1,55 % | Exelixis auf der Stifel Healthcare Conference: Zanzalintinib soll als neuer Wachstumstreiber Cabozantinib ablösen |
SILEXION THERAPEUTICS CORP gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,18 % bei einem Aktienkurs von 0,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.